Vir Biotechnology

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vir Biotechnology reports Q2 results, focuses on breakthrough therapies

Vir Biotechnology's Q2 2023 performance reflects strong financial discipline and a focus on advancing breakthrough therapies for infectious diseases.
Despite challenges in trial outcomes and treatment durations, Vir's robust cash position and diverse pipeline position it well for future growth.
The company's strategic strengths in capitalization, pipeline diversity, and commitment to medical innovation present promising opportunities for continued success.

Vir Biotechnology reports Q3 loss, eyes growth in diverse sectors

Vir Biotechnology's Q3 2023 performance reflected revenue decline, high R&D expenses, and a consolidated net loss, offset by strong financial position.
Strengths include a robust financial standing, advancements in next-generation antibodies, and application of trial learnings to enhance analysis.
Challenges encompass expansion into new sectors, regulatory criteria, and dose calibration, while opportunities exist in HIV programs and strategic expansions.
Overall, Vir Biotechnology navigates financial challenges with a focus on innovation and growth in diverse therapeutic areas.

Vir Biotechnology advances hepatitis treatments amidst financial growth and challenges

Vir Biotechnology's Q4 2023 performance reflects progress in drug development for hepatitis delta, hepatitis B, and HIV, supported by a strong financial position.
While facing challenges such as leadership transitions and pipeline restructuring, the company remains focused on clinical trial enrollment and cost management.
Opportunities lie in sharing trial data, expanding treatment regimens, and collaborating for improved disease management, positioning Vir for future growth and innovation.
Strategic allocation of resources and a commitment to advancing therapeutic solutions underscore Vir's resilience and potential for long-term success in the biopharmaceutical industry.

Vir Biotechnology excels in Q1 trials, eyes transformative growth

Vir Biotechnology's Q1 performance reflects progress in clinical trials and strategic initiatives, positioning the company for transformative growth in 2024.
Despite leadership changes and regulatory challenges, Vir Biotechnology's strong pipeline and global study designs offer resilience and potential for market success.
The upcoming data presentations and trial milestones present key opportunities for Vir Biotechnology to solidify its position in the biopharmaceutical industry and drive shareholder value.

Vir Biotechnology reports breakthrough results in hepatitis delta treatment

Vir Biotechnology's Q3 2024 earnings call highlighted promising results from the SOLSTICE trial in chronic hepatitis delta and strategic collaborations with Sanofi.
The company's financial performance and pipeline updates demonstrate a strong foundation for growth and innovation in the biopharmaceutical industry.
While facing challenges in regulatory complexities and financial management, Vir Biotechnology remains well-positioned to capitalize on opportunities in transformative therapies.
Overall, Vir's focus on advancing hepatitis programs and T-cell engagers underscores a commitment to addressing critical medical needs and driving shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN FRANCISCO, July  10, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal formerly served as Executive Vice President, Chief Scientific Officer and President of Bristol-Myers Squibb Company (BMS) Research and Development (R&D), where he played an instrumental role in bringing 14 new medicines to patients in need.

Vir Biotechnology Appoints Elliott Sigal, M.D., Ph.D. to Board of Directors

SAN FRANCISCO, July  10, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the closing of its previously announced underwritten public offering of 8,214,285 shares of its common stock at a public offering price of $42.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,071,428 additional shares of common stock. The aggregate gross proceeds to Vir from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, were approximately $345.0 million.

Vir Biotechnology Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO, July  07, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the pricing of its previously announced underwritten public offering of 7,142,857 shares of its common stock at a price to the public of $42.00 per share. The gross proceeds to Vir from the offering before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $300.0 million. The offering is expected to close on July 10, 2020, subject to satisfaction of customary closing conditions. In addition, Vir has granted the underwriters a 30-day option to purchase up to 1,071,428 additional shares of its common stock.

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO, July  06, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 6,200,000 shares of its common stock. In addition, Vir expects to grant the underwriters a 30-day option to purchase up to 930,000 additional shares of its common stock offered at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Vir Biotechnology Announces Proposed Public Offering of Common Stock

Appreciating Vir's Antibodies

Dynavax Technologies

Novavax

Higher numbers of COVID-19 cases helped these biotechs, which are working on treatments and vaccines for the disease.

Why Dynavax, Novavax, and Vir Biotechnology Stocks Jumped Today

Preclinical data for its COVID-19 treatment looked promising.

Here's Why Vir Biotechnology Jumped 12% in May

The company is an aggressive newcomer to the infectious-disease market and its COVID-19 programs are very promising.

Vir Biotechnology Is Bucking The Biotech COVID-19 Trends, And Stands To Win

Gilead Sciences

Illumina

These three biotechs are hotly traded for good reason.

3 Biotech Quick Picks to Invest $5,000 This Week

These biotech companies are both infectious disease experts and are likely to remain in the forefront when it comes to coronavirus treatment.

Better Coronavirus Stock: Gilead Sciences or Vir Biotechnology?

The company is making progress in its efforts to develop a therapy for COVID-19.

Why Vir Biotechnology Rocketed Higher Today

SAN FRANCISCO, May  18, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of research findings from the company’s efforts to develop therapeutics for COVID-19 in the May 18, 2020 issue of the journal Nature . The paper, entitled “Cross-neutralization of SARS-CoV and SARS-CoV2 by a human monoclonal antibody” (Pinto, et al., Nature), details the identification and characterization of S309, an antibody isolated from a patient who recovered from severe acute respiratory syndrome (SARS) in 2003, which has been shown to prevent SARS-CoV-2 live virus infection of cells. Vir is advancing two clinical development candidates based on the S309 antibody as potential therapeutics for COVID-19, VIR-7831 and VIR-7832, in collaboration with GlaxoSmithKline plc (LSE/NYSE: GSK).

Identification and Characterization of a Potential Therapeutic COVID-19 Antibody by Vir Biotechnology Published in Nature

Vir Bio COVID-19 Updates, And Other News: The Good, Bad And Ugly Of Biopharma

SAN FRANCISCO, May  12, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

SAN FRANCISCO, May  08, 2020  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees and others, Vir Biotechnology, Inc. is changing its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) to a virtual-only format that will be held via live audio webcast.

Vir Biotechnology Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

BioNTech SE

Catalent

GlaxoSmithKline

Johnson & Johnson

Moderna

Pfizer

Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.

Finding a Coronavirus Cure: 5 Companies Making Moves

Alnylam Pharmaceuticals

The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.

Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to Pursue

Regeneron Pharmaceuticals

While the stock markets have declined this year due to the spread of the novel coronavirus, stocks of pharma companies developing treatments and vaccines for the highly contagious viral infection have fared quite well.

Best Coronavirus Treatment Stock: Gilead, Regeneron, Or Vir?

Company to host a conference call at 2:00 p.m. PT today Company to host a conference call at 2:00 p.m. PT today

VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

Will a 14-year head start prove to be an advantage between these biotechs?

Better Buy: Alnylam Pharmaceuticals vs. Vir Biotechnology

The companies are taking multiple approaches to develop treatments and vaccines for the disease caused by the novel coronavirus.

GlaxoSmithKline and Vir Biotechnology Jump in Race to Treat and Prevent COVID-19

Vir Biotechnology (NASDAQ: VIR) shares are trading higher on Monday, after the company announced plans to work on coronavirus solutions with GlaxoSmithKline and a $250 million investment from the company.

Why Vir Biotechnology's Stock Is trading Higher Today

U.K. pharmaceutical GlaxoSmithKline GSK, -1.48% GSK, +0.33% said it's making an equity investment in Vir Biotechnology VIR, -0.88% as part of a collaboration to research and develop solutions for coronaviruses.

Vir Biotechnology shares surge on news Glaxo taking $250 million stake

LONDON and SAN FRANCISCO, April  06, 2020  (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have signed a binding agreement to enter into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19.

GSK and Vir Biotechnology enter collaboration to find coronavirus solutions

CRISPR Therapeutics

Telesis Bio Inc

These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure.

News for Vir Biotechnology Stock (VIR)